{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:18:58Z","timestamp":1791188338571,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1097\/crd.0000000000000001","type":"journal-article","created":{"date-parts":[[2013,12,4]],"date-time":"2013-12-04T09:40:46Z","timestamp":1386150046000},"page":"43-50","source":"Crossref","is-referenced-by-count":10,"title":["New Antiobesity Agents"],"prefix":"10.1097","volume":"22","author":[{"given":"Grace","family":"Shyh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Cheng-Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R7-7-20210203","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2165\/00003495-200565100-00006","article-title":"Pharmacotherapy for obesity.","volume":"65","author":"Ioannides-Demos","year":"2005","journal-title":"Drugs"},{"key":"R8-7-20210203","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1365-2125.2009.03453.x","article-title":"Pharmacotherapy for obesity.","volume":"68","author":"Li","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R9-7-20210203","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.ijo.0801889","article-title":"Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials.","volume":"26","author":"Haddock","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"R10-7-20210203","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine.","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"R11-7-20210203","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00002018-200629040-00001","article-title":"Safety of drug therapies used for weight loss and treatment of obesity.","volume":"29","author":"Ioannides-Demos","year":"2006","journal-title":"Drug Saf"},{"key":"R12-7-20210203","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.","volume":"335","author":"Abenhaim","year":"1996","journal-title":"N Engl J Med"},{"key":"R13-7-20210203","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199809103391102","article-title":"A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.","volume":"339","author":"Jick","year":"1998","journal-title":"N Engl J Med"},{"key":"R15-7-20210203","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1067\/mhj.2002.126733","article-title":"Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies.","volume":"144","author":"Sachdev","year":"2002","journal-title":"Am Heart J"},{"key":"R16-7-20210203","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archinte.164.9.994","article-title":"The efficacy and safety of sibutramine for weight loss: a systematic review.","volume":"164","author":"Arterburn","year":"2004","journal-title":"Arch Intern Med"},{"key":"R17-7-20210203","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.","volume":"363","author":"James","year":"2010","journal-title":"N Engl J Med"},{"key":"R18-7-20210203","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4093\/dmj.2012.36.1.13","article-title":"Anti-obesity drugs: a review about their effects and safety.","volume":"36","author":"Kang","year":"2012","journal-title":"Diabetes Metab J"},{"key":"R19-7-20210203","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","article-title":"Meta-analysis: pharmacologic treatment of obesity.","volume":"142","author":"Li","year":"2005","journal-title":"Ann Intern Med"},{"key":"R20-7-20210203","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0163-7258(98)00019-9","article-title":"5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function.","volume":"79","author":"Roth","year":"1998","journal-title":"Pharmacol Ther"},{"key":"R21-7-20210203","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens.","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol Ther"},{"key":"R22-7-20210203","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/374542a0","article-title":"Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors.","volume":"374","author":"Tecott","year":"1995","journal-title":"Nature"},{"key":"R23-7-20210203","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management.","volume":"363","author":"Smith","year":"2010","journal-title":"N Engl J Med"},{"key":"R25-7-20210203","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1463-1326.2010.01242.x","article-title":"Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity.","volume":"12","author":"Kang","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"R26-7-20210203","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","article-title":"Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.","volume":"325","author":"Thomsen","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"R27-7-20210203","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1021\/jm0709034","article-title":"Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.","volume":"51","author":"Smith","year":"2008","journal-title":"J Med Chem"},{"key":"R30-7-20210203","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.","volume":"96","author":"Fidler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R31-7-20210203","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","article-title":"Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.","volume":"20","author":"ONeil","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"R33-7-20210203","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0899-9007(00)00452-4","article-title":"Influence of topiramate in the regulation of energy balance.","volume":"16","author":"Richard","year":"2000","journal-title":"Nutrition"},{"key":"R34-7-20210203","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/sj.ijo.0801873","article-title":"The effects of topiramate and sex hormones on energy balance of male and female rats.","volume":"26","author":"Richard","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"R35-7-20210203","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/oby.2000.84","article-title":"Topiramate reduces energy and fat gains in lean (Fa) and obese (fafa) Zucker rats.","volume":"8","author":"Picard","year":"2000","journal-title":"Obes Res"},{"key":"R36-7-20210203","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/011542650702200150","article-title":"Pharmacologic treatment options for obesity: current and potential medications.","volume":"22","author":"Fujioka","year":"2007","journal-title":"Nutr Clin Pract"},{"key":"R38-7-20210203","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"R40-7-20210203","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phenterminetopiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"R41-7-20210203","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phenterminetopiramate in severely obese adults: a randomized controlled trial (EQUIP).","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:48:52Z","timestamp":1620949732000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-201401000-00007"}},"subtitle":["Lorcaserin (Belviq) and Phentermine\/Topiramate ER (Qsymia)"],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000001","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}